Clinical trials: BRONCHIAL ASTHMA
Seasonal Allergic Rhinitis, Asthma
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
- Trial name
- NCT02061670
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Circassia Limited
Asthma
Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.
The purpose of this study is to assess the effectiveness of JNJ-18054478 measured by the percent change from baseline in Forced Expiratory Volume in one Second (FEV1) after 12 weeks of therapy in patients with persistent asthma.
- Trial name
- NCT00530166
- Testing
- JNJ-18054478
- Where
- 36 sites in United States, Costa Rica and 1 more
- Volunteers
- 26 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Asthma
A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma
Objective: To explore the utility of Fractional Exhaled Nitric Oxide (FeNO) compared with Methacholine Challenge (MCC) testing in assessing patients with suspected but undiagnosed asthma Number of participants: Approximately 50…
- Trial name
- NCT01648920
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aerocrine AB
Chronic Obstructive Pulmonary Disease - COPD
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects
AZD8871 is a new chemical entity possessing long-acting dual-pharmacology (muscarinic receptor antagonist and β2 adrenoceptor agonist [MABA]) in a single molecule.
- Trial name
- NCT03159442
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bronchiolitis
Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma
The investigators hypothesized that oral Dexamethasone in addition to nebulized Salbutamol will improve the Bronchiolitis Clinical Severity Score,duration of treatment in the short stay unit,need for hospitalization and…
- Trial name
- #9105 (NCT01065272)
- Testing
- Dexamethasone
- Where
- Qatar
- Volunteers
- 200 people
- Sponsor
- Hamad Medical Corporation
Asthma, Bronchiectasis
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
- Trial name
- DAS181 (NCT01113034)
- Testing
- DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ansun Biopharma, Inc.
Asthma
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
The purpose of this study is to confirm equivalent bronchodilator efficacy of the test product compared to the reference product.
- Trial name
- BUFODIL (NCT02308098)
- Testing
- Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh, Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh, Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
- Where
- Bulgaria
- Volunteers
- 72 people
- Sponsor
- Orion Corporation, Orion Pharma
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Asthma
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.
- Trial name
- TRICHECO (NCT07546981)
- Testing
- Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a
- Where
- 2 sites in China
- Volunteers
- 554 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, COPD
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
- Trial name
- BufoSwitch (NCT04663386)
- Testing
- Budesonide-Formoterol
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Orion Corporation, Orion Pharma
Respiratory System Disease, Chronic Obstructive Pulmonary Disease
The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)
The purpose of the study is to prove the clinical superiority of respiratory rehabilitation software "Redpill Breath" and evaluate the clinical improvement effect by 6-minute walk test of the software, compared to the manual…
- Conditions
- Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer
- Trial name
- NCT05299385
- Testing
- Conventional rehabilition treatment(e.g leaflet) educated by hospital, Digital treatment based on Respiratory Rehabilitation Software
- Where
- 3 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Lifesemantics Corp.
Asthma
Pooled Analysis FP_SX_250_50
A pooled analysis of three bioequivalence studies conducted for Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals (Test, T) vs ADVAIR DISKUS® 250/50 mcg inhalation…
- Trial name
- NCT04790838
- Testing
- Test, Reference
- Where
- Greece
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma
Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
This is a prospective, non-comparative, open, observational study.
- Trial name
- NCT01438255
- Where
- South Korea
- Volunteers
- 274 people
- Sponsor
- Handok Inc.
COPD, Asthma
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation
- Trial name
- NCT02490358
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Bronchial Asthma
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation Aerosol) 0.04 mg/ INH with the marketed QVAR® 40 mcg (Beclomethasone dipropionate hydrofluoroalkane (HFA)) and to demonstrate superiority of…
- Trial name
- QVR (NCT04051710)
- Testing
- Test Product, Reference Product
- Where
- India
- Volunteers
- 1,550 people
- Sponsor
- Aurobindo Pharma Ltd
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Asthma
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.
- Trial name
- NCT00394654
- Testing
- MEDI-528 9 mg/kg
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- MedImmune LLC
Asthma, Exercise-Induced
Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)
The purpose of this study is to determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as…
- Trial name
- NCT00092131
- Testing
- Comparator: Montelukast
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
- Trial name
- NCT00877539
- Testing
- PF-03526299, Fluticasone propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Pfizer
Asthma
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.
- Trial name
- NCT01747629
- Testing
- Albuterol MDPI
- Where
- 35 sites in United States
- Volunteers
- 160 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.